To assess the security and effectiveness of NKG2D CAR-T cell treatment in patients with recurrent and resistant GBM, a pilot phase I study (NCT04717999) was started in 2021 and is anticipated to be completed in December 2023. Here, KLRK1 is linked to glioblastoma.